VEA
FDMT icon

Virtus ETF Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

Virtus ETF Advisers’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,333
Closed -$57.6K – 558
2024
Q4 		$57.6K Buy
10,333
+6,560
+174% +$51.5K 0.02% 454
2024
Q3 		$40.8K Buy
3,773
+64
+2% +$1.06K 0.02% 446
2024
Q2 		$77.9K Sell
3,709
-1,506
-29% -$37.8K 0.04% 415
2024
Q1 		$166K Sell
5,215
-359
-6% -$9.16K 0.09% 310
2023
Q4 		$113K Buy
5,574
+1,095
+24% +$14.4K 0.07% 325
2023
Q3 		$57K Sell
4,479
-444
-9% -$7.43K 0.03% 408
2023
Q2 		$89K Buy
4,923
+783
+19% +$14.4K 0.05% 417
2023
Q1 		$71.2K Sell
4,140
-1,591
-28% -$30.9K 0.04% 401
2022
Q4 		$127K Buy
+5,731
New +$88.5K 0.07% 398
2022
Q2 		– Sell
-7,683
Closed -$116K – 455
2022
Q1 		$116K Sell
7,683
-457
-6% -$7.18K 0.05% 274
2021
Q4 		$179K Buy
8,140
+883
+12% +$21.6K 0.07% 249
2021
Q3 		$196K Sell
7,257
-385
-5% -$11K 0.09% 275
2021
Q2 		$184K Buy
+7,642
New +$234K 0.08% 380

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Virtus ETF Advisers's FDMT Position: Q1 2025 in Review

Virtus ETF Advisers sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 10,333 shares — an estimated $57.6K sold.

Virtus ETF Advisers first reported a position in FDMT in Q2 2021 and held it in 13 quarters. The position peaked at $196K in Q3 2021. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

  • Virtus ETF Advisers reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 10,333 4D Molecular Therapeutics shares in Q1 2025, an estimated $57.6K.
  • Virtus ETF Advisers first reported a position in 4D Molecular Therapeutics in Q2 2021 and held it in 13 quarters.
  • Virtus ETF Advisers's 4D Molecular Therapeutics position peaked at $196K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.